Johnson & Johnson (JNJ) stock
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3086% above fair value
$278.70−3.85 (-1.36%)
Close on Nov 17, 2026Market cap $670.92BP/E 42.3Yield 1.84%
Johnson & Johnson cash
Cash and short-term investments held at the end of each period.
Johnson & Johnson's cash was $17.23B at Sep 27, 2026. For fiscal 2025 it was $20.10B, down 18.0% from the year before. Over ten years it grew -6.3% a year on average. The highest annual figure on record is $41.91B in fiscal 2016.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $20.10B | -18.0% |
| FY2024 | Dec 29, 2024 | $24.52B | +7.0% |
| FY2023 | Dec 31, 2023 | $22.93B | -2.5% |
| FY2022 | Jan 1, 2023 | $23.52B | -25.6% |
| FY2021 | Jan 2, 2022 | $31.61B | +25.5% |
| FY2020 | Jan 3, 2021 | $25.19B | +30.6% |
| FY2019 | Dec 29, 2019 | $19.29B | -2.0% |
| FY2018 | Dec 30, 2018 | $19.69B | +7.6% |
| FY2017 | Dec 31, 2017 | $18.30B | -56.3% |
| FY2016 | Jan 1, 2017 | $41.91B | +9.2% |
| FY2015 | Jan 3, 2016 | $38.38B | +16.0% |
| FY2014 | Dec 28, 2014 | $33.09B | +13.3% |
| FY2013 | Dec 29, 2013 | $29.21B | +38.5% |
| FY2012 | Dec 30, 2012 | $21.09B | -34.6% |
| FY2011 | Jan 1, 2012 | $32.26B | +16.6% |
| FY2010 | Jan 2, 2011 | $27.66B | +74.9% |
| FY2009 | Jan 3, 2010 | $15.81B | +46.8% |
| FY2008 | Dec 28, 2008 | $10.77B | +38.6% |
| FY2007 | Dec 30, 2007 | $7.77B | +90.3% |
| FY2006 | Dec 31, 2006 | $4.08B | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $17.23B | -7.2% |
| Q2 FY2026 | Jun 28, 2026 | $20.76B | +9.9% |
| Q1 FY2026 | Mar 29, 2026 | $22.05B | -43.1% |
| Q4 FY2025 | Dec 28, 2025 | $20.10B | -18.0% |
| Q3 FY2025 | Sep 28, 2025 | $18.56B | -8.5% |
| Q2 FY2025 | Jun 29, 2025 | $18.88B | -25.9% |
| Q1 FY2025 | Mar 30, 2025 | $38.78B | +47.9% |
| Q4 FY2024 | Dec 29, 2024 | $24.52B | +7.0% |
| Q3 FY2024 | Sep 29, 2024 | $20.30B | -13.7% |
| Q2 FY2024 | Jun 30, 2024 | $25.48B | -10.7% |
| Q1 FY2024 | Mar 31, 2024 | $26.22B | -18.9% |
| Q4 FY2023 | Dec 31, 2023 | $22.93B | -2.5% |
| Q3 FY2023 | Oct 1, 2023 | $23.51B | -31.1% |
| Q2 FY2023 | Jul 2, 2023 | $28.51B | -12.6% |
| Q1 FY2023 | Apr 2, 2023 | $32.32B | +6.3% |
| Q4 FY2022 | Jan 1, 2023 | $23.52B | -25.6% |
| Q3 FY2022 | Oct 2, 2022 | $34.13B | +10.1% |
| Q2 FY2022 | Jul 3, 2022 | $32.61B | +28.9% |
| Q1 FY2022 | Apr 3, 2022 | $30.41B | +23.5% |
| Q4 FY2021 | Jan 2, 2022 | $31.61B | +25.5% |
| Q3 FY2021 | Oct 3, 2021 | $31.00B | +0.7% |
| Q2 FY2021 | Jul 4, 2021 | $25.31B | +32.3% |
| Q1 FY2021 | Apr 4, 2021 | $24.62B | +36.6% |
| Q4 FY2020 | Jan 3, 2021 | $25.19B | +30.6% |
| Q3 FY2020 | Sep 27, 2020 | $30.78B | +71.5% |
| Q2 FY2020 | Jun 28, 2020 | $19.13B | +25.2% |
| Q1 FY2020 | Mar 29, 2020 | $18.02B | +17.5% |
| Q4 FY2019 | Dec 29, 2019 | $19.29B | -2.0% |
| Q3 FY2019 | Sep 29, 2019 | $17.94B | -7.3% |
| Q2 FY2019 | Jun 30, 2019 | $15.28B | -15.8% |
| Q1 FY2019 | Mar 31, 2019 | $15.34B | +0.9% |
| Q4 FY2018 | Dec 30, 2018 | $19.69B | +7.6% |
| Q3 FY2018 | Sep 30, 2018 | $19.36B | +19.3% |
| Q2 FY2018 | Jul 1, 2018 | $18.14B | +41.1% |
| Q1 FY2018 | Apr 1, 2018 | $15.20B | -61.4% |
| Q4 FY2017 | Dec 31, 2017 | $18.30B | -56.3% |
| Q3 FY2017 | Oct 1, 2017 | $16.23B | – |
| Q2 FY2017 | Jul 2, 2017 | $12.85B | – |
| Q1 FY2017 | Apr 2, 2017 | $39.34B | – |
| Q4 FY2016 | Jan 1, 2017 | $41.91B | – |
See a number that looks wrong?